Russian law applies distinct rules to pharmaceuticals assets when family disputes arise. Structuring early can preserve ownership. Make an enquiry.
Russian law treats pharmaceuticals-sector assets situated in Russia as common marital property by default, subject to division under the standard civil law framework – unless a valid pre-nuptial agreement, trust structure, or corporate segregation arrangement was established before the dispute arose. For family offices and advisers navigating family disputes involving Russian-situated assets in the pharmaceuticals sector, this default position has direct structural consequences.
Under Russia's civil legislation governing marital property, assets acquired during marriage are presumed jointly owned, irrespective of whose name they are registered in or how they are held corporately. Pharmaceuticals-sector assets – including shares in distribution companies, manufacturing facilities, and regulatory licences issued by Roszdravnadzor – are captured by this rule. Critically, a pharmaceuticals operating licence is personal to its holder and is not itself divisible, but the underlying company holding the licence, or the economic value it generates, may fall within the scope of a Russian court's division order. Russian courts have also demonstrated willingness to look through offshore structures holding Russian-situated assets where the beneficial owner is a Russian-domiciled spouse, which makes early structural analysis essential for family disputes involving Russia.
For an adviser or family office managing a client's Russian pharmaceuticals interests, the practical priority is to establish whether any pre-dispute structuring – a matrimonial agreement valid under Russian law, a properly constituted corporate separation, or a verified offshore arrangement – is in place and enforceable before proceedings are initiated. The Private Wealth & Asset Protection practice at Vetrov & Partners advises on the full range of protective structures available to foreign clients holding Russian-situated assets, including in the pharmaceuticals sector. For a deeper procedural context, see also our analysis at Family disputes involving Russian-situated assets and our practical guide at A practical guide to family disputes involving Russian assets.
For a confidential initial discussion, make an enquiry: info@vetrovpartners.com |
— Elizaveta Razina Senior Lawyer, Practice Lead — IP Enforcement, Vetrov & Partners vetrovpartners.com/razina/
Elizaveta Razina leads the firm's intellectual property practice, representing foreign trademark owners in infringement proceedings before Russian state courts and the IP Court. She has been with the firm since 2012 and holds a degree from Novosibirsk State University (2013). She advises on anti-counterfeiting strategy and parallel import controls.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry